In our first webinar in the NFXF’s 2025 Webinar Series, we hear updates from each of the current NIH-funded Fragile X Centers of Excellence. Why is this year’s Advocacy Day especially important? Congress is gearing up to make crucial decisions about our nation’s priorities and how to fund them. The NIH is one of those federal funding bodies supporting Fragile X research for over two decades.
The Belonging Project aims to intentionally extend our reach to underserved and underrepresented communities across the United States. We have 2025 updates from three Fragile X clinics and our belongingness survey, and we will keep you updated as we continue to move forward.
Dr. Argue shares information reviewing the details of the Congressionally Directed Medical Research Program, specifically the Peer-Reviewed Medical Research Program. Thanks to the efforts of NFXF advocates, Fragile X, which includes all FMR1-associated conditions and disorders, is once again included as an eligible topic area for FY 2025.
Announcing FY 2025 federal research funding opportunities across two award categories available for all Fragile X-associated conditions and disorders.
One of our newest initiatives aims to intentionally extend our reach to underserved communities across the United States. In partnership with four Fragile X clinics, we’ve begun work to understand the challenges to diagnosis and treatment faced by Black, Hispanic and Native American communities and the providers who serve them.
The Congressionally Directed Medical Research Program could face a 57% reduction in funding with the proposed continuing resolution.
Dr. Argue shares programmatic details, deadlines, and tips to support researchers throughout the application process, and answered questions from attendees.
In the second webinar in the NFXF’s 2024 Webinar Series, Dr. Tracy King and representatives from each of the current NIH-funded Fragile X Centers of Excellence shared updates and answered questions about their progress to date.
PureTech Health has been awarded a grant from the DOD for their trial of LYT-300, oral formulation of allopregnanolone, in people with FXTAS.
We are sharing information on a 2023 funding opportunity from CDMRP and PRMRP.
In the first webinar in the NFXF’s 2023 Webinar Series, Dr. Tracy King and representatives from each of the current NIH-funded Fragile X Centers of Excellence shared updates and answered questions about their progress to date.
The cooperative agreement was awarded to Dr Elizabeth Berry-Kravis of Rush University Medical Center by the Centers for Disease Control and Prevention.
The NIH is the biggest funder of Fragile X research – around $40M/year. That is why their strategic plan to guide Fragile X research is so important.
